1808:
658:
Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ (January 2007). "Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German
Pegvisomant Observational Study".
567:
Pegvisomant blocks the action of growth hormone on the growth hormone receptor to reduce the production of IGF-1. IGF-1 is responsible for most of the symptoms of acromegaly, and the normalization of its levels can control the symptoms.
1056:
Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, et al. (August 2006). "The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth".
1137:
194:
1011:
Evans A, Jamieson SM, Liu DX, Wilson WR, Perry JK (August 2016). "Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model".
759:
149:
430:
797:"Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant"
1130:
44:
930:
517:
and graduate student Wen Chen at the Edison
Biotechnology Institute. After completing clinical trials, it was approved for the treatment of acromegaly by the
1146:
1123:
1784:
1486:
81:
903:
Berryman DE, Palmer AJ, Gosney ES, Swaminathan S, DeSantis D, Kopchick JJ (2007). "Discovery and uses of pegvisomant: a growth hormone antagonist".
836:
770:
1566:
1828:
473:
analogues is unsuccessful, but is also effective as a monotherapy. It is delivered as a powder that is mixed with water and injected
1521:
601:
179:
62:
1309:
1833:
1798:
931:
CEDAC Final REcommendation on
Reconsideration and Reasons for Recommendation: Pegvisomant (Somavert - Pfizer Canada Inc.)
307:
98:
545:
polymers have been covalently bound in order to slow clearance from the blood. The protein is a modified version of
937:
766:
76:
1219:
1209:
579:
Some studies show the potential of using pegvisomant as an anti-tumor treatment for certain types of cancers.
260:
1167:
707:"Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY"
550:
455:
135:
1199:
474:
356:
142:
1426:
1324:
497:
Side effects of pegvisomant include reactions at the injection site, swelling of the limbs, chest pain,
251:
1466:
840:
571:
Long-term treatment studies with pegvisomant as a monotherapy have shown it to be safe, and effective.
1244:
1769:
1745:
1194:
1591:
1351:
1184:
1740:
1526:
1406:
1189:
705:
Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ (March 2015).
542:
458:
231:
1586:
1451:
1476:
1386:
1366:
1299:
1264:
1254:
1224:
1159:
1082:
993:
684:
109:
1646:
1531:
1471:
1356:
1274:
1269:
1234:
1725:
1720:
1703:
1693:
1651:
1516:
1506:
1461:
1416:
1376:
1371:
1341:
1284:
1735:
1596:
1556:
1214:
1074:
1038:
985:
912:
885:
818:
736:
676:
207:
34:
1759:
1754:
1436:
1431:
936:(Report). Canadian Agency for Drugs and Technologies in Health. 2 August 2006. Archived from
632:
1626:
1621:
1616:
1611:
1441:
1411:
1346:
1066:
1028:
1020:
975:
875:
808:
726:
718:
668:
555:
469:
tumor causing the acromegaly cannot be controlled with surgery or radiation, and the use of
372:
240:
1104:
316:
1812:
466:
837:"Ohio University, inventors to receive up to $ 52 million from drug license transactions"
1204:
1156:
731:
706:
546:
1822:
1115:
514:
997:
688:
1688:
1421:
1239:
1086:
498:
470:
162:
157:
54:
1024:
795:
Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ (June 2006).
513:
Pegvisomant was discovered at Ohio
University in 1987 by Distinguished Professor
1708:
1666:
1661:
1656:
1641:
1546:
1541:
1401:
1361:
1229:
1698:
1683:
1671:
1636:
1601:
1536:
1446:
1396:
1391:
1381:
1259:
1070:
538:
462:
411:
291:
1713:
1678:
502:
486:
48:
22:
1078:
1042:
989:
916:
889:
822:
740:
680:
880:
863:
1511:
1249:
271:
93:
813:
796:
672:
280:
1606:
722:
534:
1033:
980:
963:
1631:
522:
347:
336:
327:
213:
80:
71:
1119:
201:
88:
518:
188:
120:
1325:
1487:
437:
1310:
1796:
1770:
1151:
596:
594:
592:
1768:
1567:
1565:
1485:
1323:
1166:
839:. Ohio University. 15 February 2011. Archived from
410:
371:
366:
346:
326:
306:
290:
270:
259:
250:
230:
225:
178:
173:
148:
134:
108:
61:
43:
33:
28:
864:"Discovery and mechanism of action of pegvisomant"
1220:Placental growth hormone (growth hormone variant)
962:Neggers SJ, Muhammad A, van der Lely AJ (2015).
553:. It is manufactured using genetically modified
627:
625:
623:
239:
1131:
489:for the treatment of adults with acromegaly.
8:
700:
698:
97:
21:
1138:
1124:
1116:
1032:
979:
879:
812:
730:
315:
1803:
588:
279:
1315:Tooltip Growth hormone-binding protein
1168:
1147:
20:
964:"Pegvisomant Treatment in Acromegaly"
754:
752:
750:
355:
53:
7:
1111:. U.S. National Library of Medicine.
1059:Breast Cancer Research and Treatment
161:
335:
549:designed to bind to and block the
14:
868:European Journal of Endocrinology
801:European Journal of Endocrinology
760:Scientific Discussion of Somavert
661:European Journal of Endocrinology
1806:
389:
383:
1260:Somatrogon (MOD-4023; hGH-CTP)
465:. It is primarily used if the
401:
395:
377:
1:
1025:10.1016/j.canlet.2016.05.031
450:, sold under the brand name
1297:Antisense oligonucleotides:
602:"Somavert- pegvisomant kit"
1850:
862:Kopchick JJ (April 2003).
541:residues to which several
367:Chemical and physical data
1829:Drugs developed by Pfizer
1071:10.1007/s10549-006-9168-1
767:European Medicines Agency
637:European Medicines Agency
461:used in the treatment of
427:
1210:Human placental lactogen
521:in 2003 and marketed by
1109:Drug Information Portal
551:growth hormone receptor
456:growth hormone receptor
1602:Examorelin (hexarelin)
769:. 2004. Archived from
905:Endokrynologia Polska
881:10.1530/eje.0.148s021
1834:Receptor antagonists
1657:Pralmorelin (GHRP-2)
1200:Eftansomatropin alfa
547:human growth hormone
1699:Ibutamoren (MK-677)
1527:Modified GRF (1-29)
1427:Somatostatin (1-28)
1422:Somatostatin (GHIH)
1190:Bovine somatotropin
843:on 22 November 2016
814:10.1530/eje.1.02160
673:10.1530/eje.1.02312
639:. 17 September 2018
563:Mechanism of action
543:polyethylene glycol
197:(Prescription only)
25:
16:Pharmaceutical drug
968:Neuroendocrinology
874:(Suppl 2): S21-5.
723:10.4158/EP14330.OR
711:Endocrine Practice
608:. 18 November 2021
1794:
1793:
1776:
1749:
1573:
1493:
1467:Cyclosomatostatin
1331:
1307:Binding proteins:
1215:Lonapegsomatropin
1174:
981:10.1159/000381644
533:Pegvisomant is a
445:
444:
217:
205:
192:
124:
91:
74:
1841:
1811:
1810:
1809:
1802:
1774:
1772:
1747:
1571:
1569:
1491:
1489:
1329:
1327:
1316:
1312:
1245:Somatropin pegol
1172:
1170:
1153:
1149:
1140:
1133:
1126:
1117:
1112:
1091:
1090:
1053:
1047:
1046:
1036:
1008:
1002:
1001:
983:
959:
953:
952:
950:
948:
942:
935:
927:
921:
920:
900:
894:
893:
883:
859:
853:
852:
850:
848:
833:
827:
826:
816:
792:
786:
785:
783:
781:
775:
764:
756:
745:
744:
734:
702:
693:
692:
655:
649:
648:
646:
644:
629:
618:
617:
615:
613:
598:
441:
440:
433:
422:
420:
403:
397:
391:
385:
379:
359:
339:
319:
283:
263:
243:
215:
212:
203:
200:
190:
187:
165:
122:
119:
101:
90:
87:
84:
73:
70:
57:
26:
24:
1849:
1848:
1844:
1843:
1842:
1840:
1839:
1838:
1819:
1818:
1817:
1807:
1805:
1797:
1795:
1790:
1773:
1764:
1570:
1561:
1490:
1481:
1328:
1319:
1314:
1195:Efpegsomatropin
1171:
1162:
1144:
1103:
1100:
1095:
1094:
1055:
1054:
1050:
1010:
1009:
1005:
961:
960:
956:
946:
944:
943:on 28 June 2021
940:
933:
929:
928:
924:
902:
901:
897:
861:
860:
856:
846:
844:
835:
834:
830:
794:
793:
789:
779:
777:
776:on 18 June 2018
773:
762:
758:
757:
748:
704:
703:
696:
657:
656:
652:
642:
640:
633:"Somavert EPAR"
631:
630:
621:
611:
609:
600:
599:
590:
585:
577:
565:
537:containing 191
531:
511:
495:
485:Pegvisomant is
483:
467:pituitary gland
436:
434:
431:(what is this?)
428:
418:
416:
406:
400:
394:
388:
382:
362:
342:
322:
302:
286:
266:
246:
221:
169:
137:
130:
111:
104:
17:
12:
11:
5:
1847:
1845:
1837:
1836:
1831:
1821:
1820:
1816:
1815:
1792:
1791:
1789:
1788:
1780:
1778:
1766:
1765:
1763:
1762:
1757:
1752:
1743:
1738:
1729:
1728:
1723:
1711:
1706:
1701:
1696:
1691:
1686:
1681:
1669:
1664:
1659:
1654:
1649:
1644:
1639:
1634:
1629:
1624:
1619:
1614:
1609:
1604:
1599:
1594:
1592:Cortistatin-14
1589:
1577:
1575:
1563:
1562:
1560:
1559:
1550:
1549:
1544:
1539:
1534:
1529:
1524:
1519:
1514:
1509:
1497:
1495:
1492:(somatocrinin)
1483:
1482:
1480:
1479:
1474:
1469:
1464:
1455:
1454:
1449:
1444:
1439:
1434:
1429:
1424:
1419:
1414:
1409:
1404:
1399:
1394:
1389:
1384:
1379:
1374:
1369:
1364:
1359:
1354:
1352:Cortistatin-14
1349:
1344:
1335:
1333:
1330:(somatostatin)
1321:
1320:
1318:
1317:
1303:
1302:
1293:
1292:
1287:
1278:
1277:
1272:
1267:
1262:
1257:
1252:
1247:
1242:
1237:
1232:
1227:
1222:
1217:
1212:
1207:
1205:Growth hormone
1202:
1197:
1192:
1187:
1185:Albusomatropin
1178:
1176:
1173:(somatotropin)
1164:
1163:
1145:
1143:
1142:
1135:
1128:
1120:
1114:
1113:
1099:
1098:External links
1096:
1093:
1092:
1048:
1013:Cancer Letters
1003:
954:
922:
895:
854:
828:
787:
746:
694:
650:
619:
587:
586:
584:
581:
576:
573:
564:
561:
530:
527:
510:
507:
494:
491:
482:
479:
475:under the skin
443:
442:
425:
424:
414:
408:
407:
404:
398:
392:
386:
380:
375:
369:
368:
364:
363:
361:
360:
352:
350:
344:
343:
341:
340:
332:
330:
324:
323:
321:
320:
312:
310:
304:
303:
301:
300:
296:
294:
288:
287:
285:
284:
276:
274:
268:
267:
265:
264:
256:
254:
248:
247:
245:
244:
236:
234:
228:
227:
223:
222:
220:
219:
210:
198:
184:
182:
176:
175:
171:
170:
168:
167:
154:
152:
146:
145:
140:
138:administration
132:
131:
129:
128:
126:
116:
114:
106:
105:
103:
102:
85:
67:
65:
59:
58:
51:
41:
40:
37:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
1846:
1835:
1832:
1830:
1827:
1826:
1824:
1814:
1804:
1800:
1786:
1782:
1781:
1779:
1777:
1775:(somatomedin)
1767:
1761:
1758:
1756:
1753:
1751:
1750:-Lys³)-GHRP-6
1744:
1742:
1741:Cortistatin-8
1739:
1737:
1734:
1731:
1730:
1727:
1724:
1722:
1719:
1715:
1712:
1710:
1707:
1705:
1702:
1700:
1697:
1695:
1692:
1690:
1687:
1685:
1682:
1680:
1677:
1673:
1670:
1668:
1665:
1663:
1660:
1658:
1655:
1653:
1650:
1648:
1645:
1643:
1640:
1638:
1635:
1633:
1630:
1628:
1625:
1623:
1620:
1618:
1615:
1613:
1610:
1608:
1605:
1603:
1600:
1598:
1595:
1593:
1590:
1588:
1585:
1582:
1579:
1578:
1576:
1574:
1564:
1558:
1555:
1552:
1551:
1548:
1545:
1543:
1540:
1538:
1535:
1533:
1530:
1528:
1525:
1523:
1520:
1518:
1515:
1513:
1510:
1508:
1505:
1502:
1499:
1498:
1496:
1494:
1484:
1478:
1475:
1473:
1470:
1468:
1465:
1463:
1460:
1457:
1456:
1453:
1450:
1448:
1445:
1443:
1440:
1438:
1435:
1433:
1430:
1428:
1425:
1423:
1420:
1418:
1415:
1413:
1410:
1408:
1407:Pentetreotide
1405:
1403:
1400:
1398:
1395:
1393:
1390:
1388:
1385:
1383:
1380:
1378:
1375:
1373:
1370:
1368:
1365:
1363:
1360:
1358:
1355:
1353:
1350:
1348:
1345:
1343:
1340:
1337:
1336:
1334:
1332:
1322:
1313:
1308:
1305:
1304:
1301:
1298:
1295:
1294:
1291:
1288:
1286:
1283:
1280:
1279:
1276:
1273:
1271:
1268:
1266:
1263:
1261:
1258:
1256:
1253:
1251:
1248:
1246:
1243:
1241:
1238:
1236:
1233:
1231:
1228:
1226:
1223:
1221:
1218:
1216:
1213:
1211:
1208:
1206:
1203:
1201:
1198:
1196:
1193:
1191:
1188:
1186:
1183:
1180:
1179:
1177:
1175:
1165:
1161:
1158:
1155:
1141:
1136:
1134:
1129:
1127:
1122:
1121:
1118:
1110:
1106:
1105:"Pegvisomant"
1102:
1101:
1097:
1088:
1084:
1080:
1076:
1072:
1068:
1065:(3): 315–27.
1064:
1060:
1052:
1049:
1044:
1040:
1035:
1030:
1026:
1022:
1019:(1): 117–23.
1018:
1014:
1007:
1004:
999:
995:
991:
987:
982:
977:
973:
969:
965:
958:
955:
939:
932:
926:
923:
918:
914:
910:
906:
899:
896:
891:
887:
882:
877:
873:
869:
865:
858:
855:
842:
838:
832:
829:
824:
820:
815:
810:
806:
802:
798:
791:
788:
772:
768:
761:
755:
753:
751:
747:
742:
738:
733:
728:
724:
720:
717:(3): 264–74.
716:
712:
708:
701:
699:
695:
690:
686:
682:
678:
674:
670:
666:
662:
654:
651:
638:
634:
628:
626:
624:
620:
607:
603:
597:
595:
593:
589:
582:
580:
574:
572:
569:
562:
560:
558:
557:
552:
548:
544:
540:
536:
528:
526:
524:
520:
516:
515:John Kopchick
508:
506:
504:
501:, nausea and
500:
492:
490:
488:
480:
478:
476:
472:
468:
464:
460:
457:
453:
449:
439:
432:
426:
415:
413:
409:
376:
374:
370:
365:
358:
357:ChEMBL1201515
354:
353:
351:
349:
345:
338:
334:
333:
331:
329:
325:
318:
314:
313:
311:
309:
305:
298:
297:
295:
293:
289:
282:
278:
277:
275:
273:
269:
262:
258:
257:
255:
253:
249:
242:
238:
237:
235:
233:
229:
224:
218: Rx-only
211:
209:
199:
196:
186:
185:
183:
181:
177:
172:
164:
159:
156:
155:
153:
151:
147:
144:
141:
139:
133:
127:
118:
117:
115:
113:
107:
100:
95:
86:
83:
78:
69:
68:
66:
64:
60:
56:
52:
50:
46:
42:
38:
36:
32:
29:Clinical data
27:
19:
1733:Antagonists:
1732:
1717:
1689:Capromorelin
1676:Non-peptide:
1675:
1587:Alexamorelin
1583:
1580:
1554:Antagonists:
1553:
1503:
1500:
1459:Antagonists:
1458:
1452:Veldoreotide
1338:
1306:
1296:
1289:
1282:Antagonists:
1281:
1240:Somatotropin
1181:
1108:
1062:
1058:
1051:
1016:
1012:
1006:
974:(1): 59–65.
971:
967:
957:
945:. Retrieved
938:the original
925:
911:(4): 322–9.
908:
904:
898:
871:
867:
857:
845:. Retrieved
841:the original
831:
807:(6): 805–6.
804:
800:
790:
778:. Retrieved
771:the original
714:
710:
667:(1): 75–82.
664:
660:
653:
641:. Retrieved
636:
610:. Retrieved
605:
578:
570:
566:
554:
532:
512:
499:hypoglycemia
496:
493:Side effects
484:
481:Medical uses
471:somatostatin
451:
447:
446:
435:
429:
180:Legal status
174:Legal status
143:Subcutaneous
63:License data
18:
1709:Macimorelin
1667:Tabimorelin
1662:Relamorelin
1642:Lenomorelin
1547:Tesamorelin
1542:Somatorelin
1477:Satoreotide
1402:Pasireotide
1387:NNC 26-9100
1367:Ilatreotide
1362:Edotreotide
1300:Atesidorsen
1290:Pegvisomant
1265:Somavaratan
1255:Sometribove
1230:Somapacitan
1225:Somagrebove
947:22 December
847:21 November
780:17 February
448:Pegvisomant
423: g·mol
241:218620-50-9
226:Identifiers
99:Pegvisomant
35:Trade names
23:Pegvisomant
1823:Categories
1684:Anamorelin
1672:Ulimorelin
1647:Livoletide
1637:Ipamorelin
1537:Sermorelin
1532:Rismorelin
1472:CYN-154806
1447:Vapreotide
1397:Octreotide
1392:Octreotate
1382:Lanreotide
1357:Depreotide
1275:Somidobove
1270:Somavubove
1235:Somatosalm
1160:modulators
1034:2292/30976
765:(Report).
583:References
559:bacteria.
539:amino acid
463:acromegaly
459:antagonist
412:Molar mass
317:N824AOU5XV
292:ChemSpider
252:IUPHAR/BPS
232:CAS Number
1726:LY-444711
1721:LY-426410
1718:Unsorted:
1714:SM-130686
1704:L-692,585
1694:CP-464709
1679:Adenosine
1652:LY-444711
1581:Agonists:
1572:(ghrelin)
1517:Dumorelin
1507:ALRN-5281
1501:Agonists:
1462:BIM-23056
1417:Seglitide
1377:L-817,818
1372:L-803,087
1342:BIM-23052
1339:Agonists:
1285:G120K-hGH
1182:Agonists:
1157:signaling
529:Structure
509:Discovery
503:hepatitis
487:indicated
136:Routes of
110:Pregnancy
55:Monograph
49:Drugs.com
1813:Medicine
1787:instead.
1736:A-778193
1597:EP-51216
1584:Peptide:
1557:MZ-5-156
1512:CJC-1295
1504:Peptide:
1250:Somatrem
1079:16541323
1043:27241667
998:19588354
990:25792221
917:18058724
890:12670297
823:16728538
741:25370326
689:12121175
681:17218728
606:DailyMed
575:Research
452:Somavert
438:(verify)
272:DrugBank
150:ATC code
125: B3
112:category
94:DailyMed
39:Somavert
1760:YIL-781
1755:JMV2959
1607:Ghrelin
1437:SRIF-28
1432:SRIF-14
1087:6234700
732:4618502
556:E. coli
535:protein
454:, is a
373:Formula
281:DB00082
166:)
160: (
158:H01AX01
96::
79::
1799:Portal
1632:GHRP-6
1627:GHRP-5
1622:GHRP-4
1617:GHRP-3
1612:GHRP-1
1442:TT-232
1412:RC-160
1347:CH-275
1085:
1077:
1041:
996:
988:
915:
888:
821:
739:
729:
687:
679:
643:18 May
612:18 May
523:Pfizer
348:ChEMBL
337:D05394
208:℞-only
206:
193:
92:
82:by INN
75:
1771:IGF-1
1152:IGF-1
1083:S2CID
994:S2CID
941:(PDF)
934:(PDF)
774:(PDF)
763:(PDF)
685:S2CID
1785:here
1783:See
1522:GHRH
1488:GHRH
1326:GHIH
1311:GHBP
1154:axis
1075:PMID
1039:PMID
986:PMID
949:2014
913:PMID
886:PMID
849:2016
819:PMID
782:2011
737:PMID
677:PMID
645:2022
614:2022
387:1532
328:KEGG
308:UNII
299:none
261:7485
45:AHFS
1568:GHS
1067:doi
1029:hdl
1021:doi
1017:379
976:doi
972:103
876:doi
872:148
809:doi
805:154
727:PMC
719:doi
669:doi
665:156
519:FDA
421:.10
419:129
399:300
393:262
381:990
163:WHO
77:EMA
1825::
1716:;
1674:;
1169:GH
1148:GH
1107:.
1081:.
1073:.
1063:98
1061:.
1037:.
1027:.
1015:.
992:.
984:.
970:.
966:.
909:58
907:.
884:.
870:.
866:.
817:.
803:.
799:.
749:^
735:.
725:.
715:21
713:.
709:.
697:^
683:.
675:.
663:.
635:.
622:^
604:.
591:^
525:.
505:.
477:.
417:22
214:EU
202:US
195:S4
189:AU
121:AU
89:US
72:EU
1801::
1748:D
1746:(
1150:/
1139:e
1132:t
1125:v
1089:.
1069::
1045:.
1031::
1023::
1000:.
978::
951:.
919:.
892:.
878::
851:.
825:.
811::
784:.
743:.
721::
691:.
671::
647:.
616:.
405:7
402:S
396:O
390:N
384:H
378:C
216::
204::
191::
123::
47:/
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.